Selinexor Combination Ph 1 Study
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.
Solid Tumor Malignancy
DRUG: Selinexor|DRUG: Irinotecan
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03, Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03, From date of first dose through study completion, an average of 1 year|Establish the maximum tolerated dose (MTD) for the combination of selinexor with Irinotecan., Establish the maximum tolerated dose (MTD) for the combination of selinexor with Irinotecan., From date of first dose through study completion, an average of 1 year
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.